Iloprost
Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. Iloprost is a prostacyclin mimetic.
Clinical data | |
---|---|
Trade names | Ventavis, Ilomedine, Aurlumyn |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612032 |
License data | |
Routes of administration | Inhalation, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not determined |
Protein binding | 60% |
Metabolism | Via β-oxidation to inactive tetranor-iloprost |
Elimination half-life | 20–30 minutes |
Excretion | Renal (68%) and fecal (12%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.163.887 |
Chemical and physical data | |
Formula | C22H32O4 |
Molar mass | 360.494 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.